Chronic obstructive pulmonary disease and sudden cardiac death: The Rotterdam study

European Heart Journal

Volumn 36, Issue 27, 2015, Pages 1754-1761

  Lahousse, Lies ^a,b   Niemeijer, Maartje N ^b   Van Den Berg, Marten E ^b   Rijnbeek, Peter R ^b   Joos, Guy F ^a   Hofman, Albert ^b   Franco, Oscar H ^b   Deckers, Jaap W ^b   Eijgelsheim, Mark ^b   Stricker, Bruno H ^b,c   Brusselle, Guy G ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Netherlands Healthcare Inspectorate   (Netherlands)

Author keywords

Cardiovascular mortality; Comorbidity; General population; Sudden cardiac death

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SUDDEN CARDIAC DEATH; TREATMENT DURATION; COMPLICATION; DEATH, SUDDEN, CARDIAC; KAPLAN MEIER METHOD; MIDDLE AGED; PROSPECTIVE STUDY; RISK FACTOR;

AGED; DEATH, SUDDEN, CARDIAC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84938343502     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv121     Document Type: Article

References (43)

1. Mendis S, Puska P, Norrving B (eds). Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization; 2011.
2. Chugh SS, Reinier K, Teodorescu C, Evanado A, Kehr E, Al Samara M, Mariani R, Gunson K, Jui J. Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis 2008;51:213-228.
3. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 2007;22:39-43.
4. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998;98:2334-2351.
5. Minino AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. Natl Vital Stat Rep 2011;59:1-126.
6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2013. 2013.
7. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003;114:758-762.
8. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-1519.
9. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005;128:2640-2646.
10. Jensen MT, Marott JL, Lange P, Vestbo J, Schnohr P, Nielsen OW, Jensen JS, Jensen GB. Resting heart rate is a predictor of mortality in COPD. Eur Respir J 2013;42:341-349.
11. Shih HT, Webb CR, Conway WA, Peterson E, Tilley B, Goldstein S. Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. Chest 1988;94:44-48.
12. Yildiz P, Tukek T, Akkaya V, Sozen AB, Yildiz A, Korkut F, Yilmaz V. Ventricular arrhythmias in patients with COPD are associated with QT dispersion. Chest 2002;122:2055-2061.
13. Fuso L, Incalzi RA, Pistelli R, Muzzolon R, Valente S, Pagliari G, Gliozzi F, Ciappi G. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995;98:272-277.
14. Nishiyama K, Shizuta S, Doi T, Morimoto T, Kimura T. Sudden cardiac death after PCI and CABG in the bare-metal stent era: incidence, prevalence, and predictors. Int J Cardiol 2010;144:263-266.
15. Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP, Valsartan in Acute Myocardial Infarction Trial I. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 2009;11:292-298.
16. Hofman A, Darwish Murad S, van Duijn CM, Franco OH, Goedegebure A, Ikram MA, Klaver CC, Nijsten TE, Peeters RP, Stricker BH, Tiemeier HW, Uitterlinden AG, Vernooij MW. The Rotterdam study: 2014 objectives and design update. Eur J Epidemiol 2013;28:889-926.
17. Lahousse L, Loth DW, Joos GF, Hofman A, Leufkens HG, Brusselle GG, Stricker BH. Statins, systemic inflammation and riskof death in COPD: the Rotterdam study. Pulm Pharmacol Ther 2013;26:212-217.
18. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
19. Lahousse L, Vernooij MW, Darweesh SK, Akoudad S, Loth DW, Joos GF, Hofman A, Stricker BH, Ikram MA, Brusselle GG. Chronic obstructive pulmonary disease and cerebral microbleeds. The Rotterdam Study. Am J Respir Crit Care Med 2013;188:783-788.
20. Myerburg RJ, Interian A Jr, Mitrani RM, Kessler KM, Castellanos A. Frequency of sudden cardiac death and profiles of risk. Am J Cardiol 1997;80:10F-19F.
21. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, Camm AJ, Cappato R, Cobbe SM, Di Mario C, Maron BJ, McKenna WJ, Pedersen AK, Ravens U, Schwartz PJ, Trusz-Gluza M, Vardas P, Wellens HJ, Zipes DP. Task force on sudden cardiac death of the European Societyof Cardiology. Eur Heart J 2001;22:1374-1450.
22. Niemeijer MN, van den Berg ME, Leening MJ, Hofman A, Franco OH, Deckers JW, Heeringa J, Rijnbeek PR, Stricker BH, Eijgelsheim M. Declining incidence of sudden cardiac death from 1990-2010 in a general middle-aged and elderly population: the Rotterdam study. Heart Rhythm 2015;12:123-129.
23. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
24. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995;51: 524-532.
25. Stewart AG, Waterhouse JC, Howard P. The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD. Respir Med 1995;89:79-84.
26. European Medicines Agency. ICH Topic E 14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-arrhythmic drugs. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073161.pdf (11 November 2013).
27. Sievi NA, Clarenbach CF, Camen G, Rossi VA, van Gestel AJ, Kohler M. High prevalence of altered cardiac repolarization in patients with COPD. BMC Pulm Med 2014;14:55.
28. de Miguel Diez J, Chancafe Morgan J, Jimenez Garcia R. The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis 2013;8:305-312.
29. Tirlapur VG, Mir MA. Nocturnal hypoxemia and associated electrocardiographic changes in patients with chronic obstructive airways disease. N Engl J Med 1982;306:125-130.
30. Agusti A, Hedner J, Marin JM, Barbe F, Cazzola M, Rennard S. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev 2011;20:183-194.
31. Suissa S, Dell'Aniello S, Ernst P. Long-term natural historyof chronicobstructivepulmonary disease: severe exacerbations and mortality. Thorax 2012;67:957-963.
32. Hoiseth AD, Neukamm A, Karlsson BD, Omland T, Brekke PH, Soyseth V. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax 2011;66:775-781.
33. Bernasconi M, Tamm M, Bingisser R, Miedinger D, Leuppi J, Muller B, Christ-Crain M, Stolz D. Midregional proatrial natriuretic peptide predicts survival in exacerbations of COPD. Chest 2011;140:91-99.
34. Hoiseth AD, Omland T, Hagve TA, Brekke PH, Soyseth V. NT-proBNP independently predicts long term mortality after acute exacerbation of COPD - a prospective cohort study. Respir Res 2012;13:97.
35. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased riskof myocardial infarction and stroke following exacerbation of COPD. Chest 2010;137:1091-1097.
36. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007;370:786-796.
37. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:71-78.
38. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006;61:849-853.
39. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
40. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-1397.
41. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002;105:2595-2599.
42. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, Crim C, Yates JC, Silverman EK, Coxson HO, Bakke P, Mayer RJ, Celli B, Evaluation of CLtIPSEI. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 2012;7:e37483.
43. Leening MJ, Heeringa J, Deckers JW, Franco OH, Hofman A, Witteman JC, Stricker BH. Healthy volunteer effect and cardiovascular risk. Epidemiology 2014;25:470-471.